Signs, Symptoms and Antidotes of Common Poisons

Record observed findings before deciding what they mean. Relevant information includes respiratory rate and effort, level of consciousness, pupil size, secretions, sweating, temperature, pulse, blood pressure, muscle activity and gastrointestinal findings. A fixed examination order must not delay assessment of an immediately life-threatening problem.

The table describes typical patterns. Findings may be absent, incomplete or mixed. An opioid exposure, for example, need not produce pinpoint pupils, and skin moisture is not a reliable exclusion criterion. A person with both stimulant and sedative exposure may not fit either textbook column.

Sweating can help distinguish sympathomimetic from anticholinergic presentations when assessed with the rest of the examination. It is not an infallible binary test. Likewise, excess secretions and fasciculations can suggest cholinergic toxicity in a person with small pupils, but the complete presentation and differential diagnosis remain important.

Toxidromes are observations during life. Autopsy findings cannot simply recreate the same physiological pattern. Medical records, responder observations and treatment times may therefore be more informative than an isolated post-mortem description.

Acetylcholinesterase inhibition can increase acetylcholine signalling at muscarinic, nicotinic and central sites. Muscarinic effects include secretions and bronchoconstriction; nicotinic effects include fasciculations and weakness. Respiratory compromise can involve secretions, bronchospasm, neuromuscular weakness and central effects together.

Atropine blocks muscarinic receptors. It does not reactivate acetylcholinesterase or directly reverse every nicotinic effect. The relevant clinical response is broader than pupil size or a single heart-rate target. Pralidoxime is an enzyme-reactivating treatment used for selected organophosphate exposures; its role depends on the agent and clinical circumstances, and should not be reduced to one universal time cutoff or automatically assigned to every carbamate exposure.

Other mechanisms can produce cholinergic findings. Muscarine-containing mushrooms differ from acetylcholinesterase-inhibiting pesticides. Amanita muscaria is a poor simple example of a muscarinic syndrome: ibotenic acid and muscimol are associated with central excitation and depression. A mushroom name is not enough to select a treatment pathway.

Forensic testing should distinguish evidence of enzyme inhibition from identification of the causative compound. Cholinesterase activity can be affected by baseline variation, timing, specimen conditions and treatment. A reduced value does not uniquely name an organophosphate, and a compatible pesticide container still requires independent examination.

Product names and active ingredients must be checked rather than copied from memory. Different formulations and mixtures can change exposure and interpretation. The referral should include the actual product information and preserve uncertainty where its contents have not been tested.

Anticholinergic delirium can arise from medicines or plant tropane alkaloids. Some implicated medicines also affect cardiac conduction or cause seizures through other mechanisms. A single label such as anticholinergic therefore does not capture all the risks in a mixed or tricyclic-antidepressant exposure.

Opioid toxicity can involve life-threatening respiratory depression. Naloxone antagonises opioid receptors, but response can be temporary and does not eliminate the need for emergency care and monitoring. Injectable preparations and prefilled nasal sprays have different instructions; an injectable amount must not be copied as a universal intranasal dose.

A clinical response to naloxone supports an opioid contribution in the appropriate circumstances, but it is not an analytical identification of a particular opioid. A lack of complete response does not establish that opioids were absent, especially with mixed exposure or other causes of unconsciousness. Record breathing and consciousness before and after treatment.

Sympathomimetic findings can overlap with anticholinergic toxicity, serotonin toxicity, withdrawal and non-toxicological illness. Hyperthermia, marked agitation or cardiovascular instability require urgent professional assessment. Substance-specific mechanisms and complications matter more than a reflex antidote choice from the pattern alone.

Benzodiazepines and other sedatives can depress consciousness, particularly with other depressants. Flumazenil is a benzodiazepine-receptor antagonist used in selected clinical circumstances; empirical use in an unknown mixed overdose or a person with benzodiazepine dependence can be hazardous. Reversal of sedation is not universally the safest objective.

Alcohol-related presentations may include hypoglycaemia, head injury, co-exposure or nutritional illness. Do not attribute coma to alcohol solely because alcohol was detected. Clinical records should show the evaluation and treatment of competing causes, including glucose abnormalities. A blanket instruction to delay urgent glucose until a vitamin is given is inappropriate.

Antidotes can block a receptor, prevent toxic metabolite formation, support detoxification, bind a toxin or facilitate removal. Their names are useful for interpreting treatment records, but dose, route, duration and stopping criteria require the relevant clinical guidance. Several agents may need more than an antidote, including respiratory support or extracorporeal treatment.

Acetaminophen is also called paracetamol. Acetylcysteine reduces the risk or extent of liver injury in appropriate acetaminophen exposures. Assessment differs between a known-time acute ingestion and repeated supratherapeutic or unknown-time exposure. The US ACETADOTE label includes different infusion regimens under specified conditions; a single regimen should not be described as the global standard or attributed to one hospital as its universal origin.

An antidote can also complicate the laboratory picture. Treatment may change the substance's concentration, the measured physiological marker or the behaviour of an assay. The report should identify relevant treatment and distinguish a pre-treatment specimen from one collected afterwards.

The mechanism diagram links selected antidotes to different targets. Naloxone competes at opioid receptors and atropine blocks muscarinic acetylcholine receptors. Acetylcysteine supplies a precursor for glutathione support in acetaminophen toxicity. Fomepizole inhibits alcohol dehydrogenase, limiting formation of toxic metabolites from the relevant alcohols.

Hydroxocobalamin binds cyanide through its cobalt centre to form cyanocobalamin. Digoxin-specific Fab fragments bind digoxin, reducing freely available drug; later assay interpretation can therefore be complicated. These examples explain why one antidote cannot be substituted for another merely because both patients are unconscious.

Immediate clinical care takes priority over forensic collection. Assessing airway, breathing, circulation, consciousness, glucose and other urgent problems belongs to trained responders and clinicians using current local guidance. Apparent stability at first contact does not exclude delayed toxicity.

Where feasible without delaying care, appropriately collected early specimens can help establish exposure. Record the actual collection time, matrix and relevant treatment. A specimen taken after resuscitation may answer a different question from one taken before treatment; neither should be relabelled as if the timing were known when it is not.

Antidote access is an operational issue. US poison-control and specialist services, UK clinical poisons services, Indian regional services and equivalent services elsewhere operate within different systems. Stocking recommendations are not proof of real-time availability at a particular facility. Check the current service and pharmacy arrangements rather than relying on a static list of hospitals.

Transport and storage requirements depend on the specific product and formulation. Do not claim that every antivenom or oxime has the same cold-chain requirement. Procurement, expiry monitoring, appropriate quantities and rapid referral pathways are separate from the scientific indication for treatment.

The useful forensic record includes the observed findings, suspected exposure, advice obtained, treatment given and the patient's response. A later analyst should be able to reconstruct what was observed before intervention and what changed afterwards, without assuming that treatment itself confirmed the diagnosis.

One recurring error is treating a pattern as a unique diagnosis. A container, pupil finding or odour can focus attention but must not end the differential diagnosis. The same principle applies to a positive screening test: the result should be interpreted according to its actual selectivity and scope.

Another error is copying a treatment number without its conditions. Intranasal and injectable naloxone are not interchangeable dosing formats; paediatric treatment cannot always be obtained by scaling an adult number. Modified-release exposure and co-ingestion can also change monitoring needs.

Gastrointestinal decontamination is not routine for every ingestion. Gastric lavage and activated charcoal have specific limitations and risks, and neither is a general home response to poisoning. Clinical decisions require assessment of the substance, timing, airway and likely benefit. Do not recommend inducing vomiting.

A failed clotting test after a suspected snakebite requires expert interpretation in the clinical setting. It does not uniquely identify a snake species, and a single locally used antivenom schedule cannot be applied worldwide. Regional products and validated assessment methods matter.

Outcome studies should be read with their population, severity and period in view. Results from one hospital cohort may not transfer to another setting. Antidote availability also varies between services, so emergency planning requires confirmation of local stocks and referral arrangements.

Gas and alcohol testing is developed in Gases and Volatile Poisons: CO, Cyanide, Methanol, Ethanol.

Pesticide mechanisms and analysis are developed in Pesticide Poisoning: OP, Carbamate, Pyrethroid, Aluminium Phosphide.

Regional antivenom and envenomation issues are developed in Animal and Venomous Poisons: Snakebite, Insect and Marine.